Navigation Links
Codeine not safe for all breastfeeding moms and their babies
Date:8/20/2008

Using pain treatments which contain codeine may be risky for some breastfeeding mothers, according to researchers at The University of Western Ontario, and the Hospital for Sick Children (SickKids) in Toronto. Lead author Dr. Gideon Koren published research in the journal, Clinical Pharmacology & Therapeutics which suggests that the codeine used in some pain relief drugs can actually have harmful and even fatal results for infants when ingested by some breastfeeding mothers.

"With nearly half of all infants in North America being delivered by caesarean section or after episiotomy, there is clearly a requirement for pain relief for mothers," says Koren. "However, our study confirms that codeine as a treatment for pain may be unsuitable and cannot be considered safe for all breastfed infants."

Koren holds the Ivey Chair in Molecular Toxicology at the Schulich School of Medicine & Dentistry at The University of Western Ontario, and is a professor of pediatrics at both Western and the University of Toronto. He is also a senior scientist in the Child Health Evaluative Sciences program at SickKids Research Institute, and director of The Motherisk Program.

Codeine is commonly used for pain relief and is recommended by the American Academy of Pediatrics as being compatible with breastfeeding. Following numerous reports through the Motherisk counseling service and the tragic death of an infant who died from an overdose of morphine acquired from breast milk, Koren and his team, located at SickKids and The University of Western Ontario, investigated these negative reactions.

Codeine is a 'prodrug' which means that on its own it is relatively inactive. The pain relieving attributes are only activated when it is metabolized, or transformed by the body into a more active pain relieving compound, morphine. Some individuals have a genetic variance which causes them to metabolize codeine at a rapid rate, producing signific
'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Page: 1 2

Related biology news :

1. New breastfeeding study shows most moms quit early
2. Early cessation of breastfeeding by HIV+ women in poor countries and child survival
3. Breastfeeding boost IQ in infants with helpful genetic variant
4. Parents shape whether their children learn to eat fruits and vegetables
5. Guilt on their hands: tiny tags could help to solve and deter gun crime
6. Male fish deceive rivals about their top mate choice
7. Syracuse University scientists discover how some bacteria may steal iron from their human hosts
8. Ultrasonic frogs can tune their ears to different frequencies
9. Pregnant mice block out unwelcome admirers to protect their pups
10. Researchers catch ion channels in their opening act
11. Children born after donor insemination should be told as soon as possible about their conception
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3